Cullinan Therapeutics, Inc. (CGEM) — Financial statements
Income statement, balance sheet, and cash flow for Cullinan Therapeutics, Inc. — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00↓100.0% | 19 | |
| Cost of Revenue | 0.00↓100.0% | 0.31 | 0.00 | 0.00 | 0.00 | |
| Gross Profit | 0.00↑100.0% | -0.31 | 0.00 | 0.00↓100.0% | 19 | |
| Operating Expenses | ||||||
| R&D Expenses | 187↑31.1% | 143↓3.5% | 148↑61.1% | 92↑59.2% | 58 | |
| General & Administrative Expenses | 54↑2.7% | 53↑24.3% | 42↑5.7% | 40↑37.9% | 29 | |
| Selling & Marketing Expenses | 0.00↓100.0% | 0.89 | 0.00 | 0.00 | 0.00 | |
| SG&A Expenses | 54↑1.0% | 54↑26.4% | 42↑5.7% | 40↑37.9% | 29 | |
| Other Expenses | 0.00 | 0.00↓100.0% | 0.44↑100.2% | -277 | 0.00 | |
| Operating Expenses | 242↑22.9% | 197↑2.9% | 191↑232.1% | -145↓266.5% | 87 | |
| Total Costs & Expenses | 242↑22.7% | 197↑3.1% | 191↑232.1% | -145↓266.5% | 87 | |
| Operating Results | ||||||
| Operating Income | -242↓22.7% | -197↓3.1% | -191↓232.1% | 145↑312.9% | -68 | |
| Depreciation & Amortization | 0.31↑1.6% | 0.31↓1.3% | 0.31↑233.3% | 0.09↑75.5% | 0.05 | |
| EBITDA | -241↓44.4% | -167↑12.2% | -190↓44.1% | -132↓94.5% | -68 | |
| EBIT | -242↓44.3% | -167↑12.2% | -191↓44.3% | -132↓94.5% | -68 | |
| Interest & Other Income | ||||||
| Net Interest Income | 22↓25.1% | 30↑37.1% | 22↑227.1% | 7↑1286.0% | 0.48 | |
| Interest Income | 22↓25.1% | 30↑37.1% | 22↑227.1% | 7↑1286.0% | 0.48 | |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Non-Operating Income | 0.00↑100.0% | -29↓6595.7% | -0.44↓100.2% | 277 | 0.00 | |
| Other Income / Expenses | 22↓26.1% | 29↑34.7% | 22↑227.9% | 7↑1321.7% | 0.47 | |
| Income Before Tax | -220↓31.3% | -167↑1.0% | -169↓211.8% | 151↑324.2% | -67 | |
| Income Tax Expense | 0.00↓100.0% | 0.12↑100.8% | -14↓133.5% | 42 | 0.00 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | -220↓31.2% | -168↓8.0% | -155↓242.0% | 109↑261.8% | -67 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | -220↓31.4% | -167↓9.3% | -153↓237.7% | 111↑269.6% | -66 | |
| Bottom-Line Net Income | -220↓31.4% | -167↓9.3% | -153↓237.7% | 111↑269.6% | -66 | |
| EPS (Basic) | -3.72↓19.6% | -3.11↑15.7% | -3.69↓250.0% | 2.46↑266.2% | -1.48 | |
| EPS (Diluted) | -3.72↓19.6% | -3.11↑15.7% | -3.69↓255.0% | 2.38↑260.8% | -1.48 | |
| Weighted Average Shares | 59↑9.8% | 54↑29.5% | 42↓8.1% | 45↑2.0% | 44 | |
| Weighted Average Diluted Shares | 59↑9.8% | 54↑29.4% | 42↓10.9% | 47↑5.3% | 44 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.